450 related articles for article (PubMed ID: 22183781)
1. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
Brzana JA; Yedinak CG; Delashaw JB; Gultelkin HS; Cook D; Fleseriu M
Pituitary; 2012 Dec; 15(4):562-70. PubMed ID: 22183781
[TBL] [Abstract][Full Text] [Related]
2. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
3. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
[TBL] [Abstract][Full Text] [Related]
4. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
[TBL] [Abstract][Full Text] [Related]
5. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
6. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
7. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
8. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
[TBL] [Abstract][Full Text] [Related]
9. DISCORDANCE BETWEEN GH AND IGF-1 LEVELS IN TURKISH ACROMEGALIC PATIENTS.
Cerit ET; Ağbaht K; Demir Ö; Şahin M; Gedik VT; Özcan C; Çorapçıoğlu D
Endocr Pract; 2016 Dec; 22(12):1422-1428. PubMed ID: 27631850
[TBL] [Abstract][Full Text] [Related]
10. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
Serri O; Beauregard C; Hardy J
J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
[TBL] [Abstract][Full Text] [Related]
11. 2010 versus the 2000 consensus criteria in patients with normalised insulin-like growth factor 1 after transsphenoidal surgery has high predictive values for long-term recurrence-free survival in acromegaly.
Shen M; Chen Z; Shou X; He W; Qiao N; Ma Z; Ye Z; Zhang Y; Zhang Q; Zhou X; Cao X; Zhang Z; Ye H; Li Y; Zhao Y; Li S; He M; Wang Y
J Neuroendocrinol; 2021 May; 33(5):e12958. PubMed ID: 33998086
[TBL] [Abstract][Full Text] [Related]
12. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
[TBL] [Abstract][Full Text] [Related]
13. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.
Sheaves R; Jenkins P; Blackburn P; Huneidi AH; Afshar F; Medbak S; Grossman AB; Besser GM; Wass JA
Clin Endocrinol (Oxf); 1996 Oct; 45(4):407-13. PubMed ID: 8959078
[TBL] [Abstract][Full Text] [Related]
14. Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.
Zeinalizadeh M; Habibi Z; Fernandez-Miranda JC; Gardner PA; Hodak SP; Challinor SM
Pituitary; 2015 Feb; 18(1):48-59. PubMed ID: 24496953
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy.
Kinoshita Y; Tominaga A; Usui S; Arita K; Sakoguchi T; Sugiyama K; Kurisu K
Neurosurg Rev; 2016 Apr; 39(2):313-8; discussion 318-9. PubMed ID: 26785642
[TBL] [Abstract][Full Text] [Related]
16. Value of Early Post-Operative Growth Hormone Testing in Predicting Long-Term Remission and Residual Disease after Transsphenoidal Surgery for Acromegaly.
Wang YY; Waqar M; Abou-Zeid A; Kearney T; Caputo C; Davis J; Trainer P; Higham C; Roncaroli F; Gnanalingham KK
Neuroendocrinology; 2022; 112(4):345-357. PubMed ID: 34052822
[TBL] [Abstract][Full Text] [Related]
17. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
[TBL] [Abstract][Full Text] [Related]
18. Dynamic tests and basal values for defining active acromegaly.
Tzanela M
Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
[TBL] [Abstract][Full Text] [Related]
19. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
Kaltsas GA; Isidori AM; Florakis D; Trainer PJ; Camacho-Hubner C; Afshar F; Sabin I; Jenkins JP; Chew SL; Monson JP; Besser GM; Grossman AB
J Clin Endocrinol Metab; 2001 Apr; 86(4):1645-52. PubMed ID: 11297598
[TBL] [Abstract][Full Text] [Related]
20. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]